Incyton — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Incyton GmbH is a privately-held, Dresden-based company that has developed the CYRIS® platform, a smart technology for real-time, label-free, multisensor cell analysis. The company positions itself at the intersection of biology and technology, aiming to shift cell-based assays from endpoint to kinetic measurement to improve the predictive power of preclinical research, particularly in toxicology, oncology, and metabolic profiling. While leveraging AI and machine learning for data analysis, Incyton's business model appears to be a mix of Platform (selling hardware/software) and Services (custom assay development), serving as a tools and collaboration partner for pharmaceutical companies and research institutions. Founded as a spin-off from HP Medizintechnik GmbH, the company is in an early revenue stage, focusing on instrument placement and research collaborations.

OncologyMetabolic DisordersToxicology

Technology Platform

CYRIS® multisensor platform for label-free, real-time, simultaneous monitoring of multiple cellular key parameters, combined with AI/ML for data analysis.

Opportunities

The growing demand for more predictive, physiologically relevant in vitro models in drug discovery creates a significant market for advanced cell analysis tools.

Incyton's kinetic, multiparametric approach can differentiate it from traditional endpoint assays, offering a compelling value proposition to reduce preclinical attrition.

Expansion into new application areas like immuno-oncology and strategic partnerships with larger pharma or distributors could accelerate growth.

Risk Factors

Key risks include slow adoption of a new technological paradigm against established methods, intense competition from larger, well-funded incumbents in the cell analysis space, and execution challenges related to scaling manufacturing, support, and sales as a small, private company.

Technological obsolescence is also a constant threat in a fast-moving field.

Competitive Landscape

Incyton competes in the cell-based analysis and label-free detection market against major players like Agilent (ACEA Biosciences), Molecular Devices, and NanoTemper. Its differentiation lies in its integrated, real-time multiparametric sensor platform and its focus on kinetic data. It faces competition from both high-content screening systems and other label-free technologies, requiring clear communication of its unique integrated value.

More companies in Biologics / Biosimilars →More companies in Germany →